Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancer
New Podcast
Skip to content
FOR INVESTORS
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Onvansertib
Pipeline
Clinical Programs
mCRC
mCRPC
mPDAC
Leadership
Management Team
Board of Directors
Scientific Advisory Board
Contact Us
For Investors
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Investor Relations
SEC Filings
CRDF
Year
Trailing 12-Months
Calendar Year 2023
Calendar Year 2022
Calendar Year 2021
Calendar Year 2020
Calendar Year 2019
Calendar Year 2018
Calendar Year 2017
Calendar Year 2016
Calendar Year 2015
Calendar Year 2014
Calendar Year 2013
Calendar Year 2012
Calendar Year 2011
Calendar Year 2009
Calendar Year 2008
Calendar Year 2007
Calendar Year 2006
Calendar Year 2005
Calendar Year 2004
Calendar Year 2003
View
All Filings
Annual Filings
Quarterly Filings
Current Filings
Registration Statements
Section 16
Proxy & Information Statements
Other
Form
Description
Date
Format
10-K
Annual report which provides a comprehensive overview of the company for the past year
Mar 17, 2014
Open Annual report which provides a comprehensive overview of the company for the past year in HTML.
Open Annual report which provides a comprehensive overview of the company for the past year in DOC file.
Open Annual report which provides a comprehensive overview of the company for the past year in PDF file.
Open Annual report which provides a comprehensive overview of the company for the past year in XLS file.
Open Annual report which provides a comprehensive overview of the company for the past year in XBLR Viewer.
Open Annual report which provides a comprehensive overview of the company for the past year in XBLR file.